IVE's 'EMPATHY' Is Out Today — The Group Targets a Fourth Consecutive Million-Seller on Hanteo

IVE releases EMPATHY today, February 3, their third mini album built around two title tracks and positioned to deliver a fourth consecutive first-week million-seller on Hanteo Chart. The six-track release arrives with pre-order data already establishing demand at a scale consistent with IVE's previous three releases, each of which crossed the one-million first-week sales threshold in their respective release windows. Whether EMPATHY matches that trajectory will become clear in the next 24 hours — but the day's opening hours have already answered the question of audience intent.

The commercial machinery surrounding EMPATHY's release is, at this point, a known quantity. IVE's trajectory from "Eleven" through I'VE IVE (2023), I'VE MINE, and IVE SWITCH (2024) has established a system: strong pre-orders, a concentrated first-day purchasing burst from Zerose, and a sustained streaming presence through the promotional window. What EMPATHY adds to that system is a new structural element — the double title track — and a nine-month developmental gap that raises a different kind of question: not whether IVE can sell, but whether the extended investment in this album produces music that expands the group's audience rather than simply serving its existing one.

IVE's Commercial Record Heading Into EMPATHY

The three albums preceding EMPATHY each established a different aspect of IVE's commercial profile. I'VE IVE, their first mini album released in April 2023, was the release that confirmed "Love Dive" and "After Like"'s success was not transient — it crossed the first-week million-seller threshold and positioned IVE as the dominant fourth-generation female group on Hanteo. I'VE MINE followed in October 2023, maintaining the run. IVE SWITCH in May 2024 accelerated it further, crossing one million copies in three days — at the time the second-fastest K-pop girl group album to do so.

Each successive release has arrived with cleaner market dominance: fewer competing releases at similar scale in the same window, a consolidated fandom that has grown rather than plateaued, and an increasingly professional promotional apparatus that treats each comeback not as a single event but as a multi-week commercial campaign. EMPATHY inherits all of that infrastructure — and adds the nine-month gap's accumulated anticipation to it.

The Double Title Tracks in Context

Both "Rebel Heart" and "Attitude" carry title track designation, which means both will compete for the promotional infrastructure typically reserved for one. "Rebel Heart," the pre-release single from January 13, has already demonstrated chart viability — its three-week run ahead of the album's release translated into sustained domestic streaming and social media engagement before the full EP arrived. "Attitude" represents the album's complementary argument, arriving today alongside five other tracks as the full release expands the commercial and sonic footprint of what "Rebel Heart" established.

The decision to invest a full title-track campaign in two songs simultaneously is a bet that IVE's promotional capacity can sustain both without either being underserved. In the K-pop system, where music show performances, broadcast schedules, and streaming campaign logistics all converge around a single title track, the double-title approach requires twice the execution capacity. For a group of IVE's commercial standing, that capacity exists — but the strategy only succeeds if both songs find audiences that complement rather than cannibalize each other.

The Fourth Consecutive Million-Seller: What It Would Mean

If EMPATHY crosses the one-million first-week threshold — as its pre-order trajectory suggests it will — IVE would become only the second girl group in Hanteo Chart history to achieve four consecutive albums surpassing one million first-week sales. The only other group to have reached that benchmark is aespa, which has sustained consecutive million-seller status through five albums. The pairing of IVE and aespa as the only representatives of this benchmark reflects both groups' standing as the commercial ceiling of the fourth-generation female idol landscape.

The comparison also illuminates the benchmark IVE is approaching. aespa achieved its fifth consecutive million-seller with "Whiplash" in October 2024 — the current high-water mark for fourth-generation girl group physical sales consistency. IVE, having built its run through the same post-debut period, now sits one behind. What the EMPATHY release does is confirm that the commercial foundation IVE constructed across 2022 and 2023 has not eroded during the nine-month gap, and that the group's fanbase has remained mobilized through the extended wait.

What the Release Day Reveals

The Hanteo tracking that opens the moment EMPATHY becomes available for purchase is, in the immediate term, a measure of fandom infrastructure: how efficiently Zerose converts pre-order enthusiasm into first-day certified purchases. But it is also, in a broader sense, a test of whether the nine-month gap has intensified or dissipated the fanbase's purchasing behavior. Extended gaps can work in either direction — the wait compounds demand, or the wait allows attention to drift elsewhere. Pre-order volumes suggest the former.

Beyond the numbers, February 3 is the day the music itself becomes available for critical assessment. "Rebel Heart" has already demonstrated that IVE can operate in a harder, more assertive register than their earlier commercial peaks. "Attitude," arriving today, will answer whether the double-title strategy produces two genuinely distinct listening experiences or whether the two tracks blur into a single tonal argument. The first day of streaming — not just purchasing — will tell that story. In the days that followed, EMPATHY would go on to record 619,103 first-day copies on Hanteo and surpass one million total within five days, confirming that the gap-period investment had found its audience at full volume.